Niacin acts on the GPR109A receptor in adipose tissue, reducing lipolysis (free fatty acid release). With fewer free fatty acids reaching the liver, VLDL production decreases → triglycerides drop 20-50% → and as a consequence, HDL increases 20-35%. The flush is also mediated by GPR109A — it triggers prostaglandin D2 release in skin, causing vasodilation, warmth, and itching. Extended-release formulations slow the peak activation, reducing flush. At RDA doses, niacin serves as a precursor to NAD+/NADH, essential for 400+ enzymatic reactions.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.